Re: Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = prostate cancer: authors' reply

Pathology

Volumn 47, Issue 4, 2015, Pages 394-395

  Sieh, Weiva ^a   Lichtensztajn, Daphne Y ^b   Gomez, Scarlett Lin ^b   Liu, Jen Jane ^a   Chung, Benjamin I ^a   Cheng, Iona ^b   Brooks, James D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; HUMAN; LYMPH NODE METASTASIS; MALE; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; HUMANS; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS;

EID: 84941338966     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000264     Document Type: Article

References (4)

1. 1. Kryvenko, O.N., Epstein, J.I., Re: Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer. Pathology, 47, 2015, 394.
2. 2. Ross, H.M., Kryvenko, O.N., Cowan, J.E., et al. Do adenocarcinomas of the prostate with Gleason score (GS)
3. 3. Brimo, F., Schultz, L., Epstein, JI., The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. J Urol 184 (2010), 126–130.
4. 4. McKenney, J.K., Simko, J., Bonham, M., et al. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol 186 (2011), 465–469.